Optimizing Care for Lower-Risk Myelodysplastic Syndromes: Translating Evidence to Clinical Practice - Episode 9
Panelists discuss how luspatercept’s role in ring sideroblast–negative MDS populations is evolving based on recent clinical trial data, including the COMMANDS trial and PACE-MDS study, with particular attention to the impact ofEPO levels on treatment decisions and outcomes.
Video content above is prompted by the following:
Resource link: COMMANDS trial (Della Porta MG, et al. Lancet Haematol, 2024).
Resource link: Platzbecker U, et al. Phase II PACE-MDS study. J Clin Oncol, 2022.
Resource link: Platzbecker U, et al. Comparative biomarkers by RS status COMMANDS trial. EHA 2024, abstract P763.